Extraskeletal Ewing's sarcoma arising in the head and neck region is an extremely rare malignant neoplasm. We describe the unusual case of a tumor originating in the larynx of a 68-year-old male with hoarseness and occasional aphonia. We report successful treatment with sequential chemo- and radiotherapy. Complete regression and larynx preservation with voice function recovery was achieved. To our knowledge, this is the first report of this type of tumor in the larynx with cartilage invasion that documents the effectiveness of radiotherapy as an alternative to surgical management. At present, after 30 months of follow-up, the patient is free of tumor relapse and in very good condition.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00066-013-0356-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary cutaneous/subcutaneous Ewings sarcoma.
Bull Cancer
March 2025
Pediatric Oncology, insitut Gustave-Roussy, Villejuif, France. Electronic address:
Amongst Ewing sarcoma family of tumours, (EFST), cutaneous/subcutaneous Ewing sarcoma are defined as tumours arising from cutaneous or subcutaneous tissue, not invading the underlying aponeurosis. They are rare tumours, with less than 200 patients published. They are typically small tumours (less than 5cm), and can arise at any anatomical location, with a particular tropism for distal, truncal and head/neck locations, compared to classical Ewing sarcoma.
View Article and Find Full Text PDF[Extra-pulmonary metastatic Ewing sarcoma: The French GroupOs diagnostic and therapeutic recommendations].
Bull Cancer
March 2025
Oncologie médicale, Institut Curie, Paris, France.
Patients who develop Ewing sarcoma with extra-pulmonary metastasis have a poor prognosis. A recent French protocol, CombinaiR3, was set up to evaluate the efficacy of induction chemotherapy followed by high-dose chemotherapy and metronomic maintenance treatment. It is now closed for inclusions and while waiting for the results, we propose a French consensus guideline for the management of patients diagnosed with Ewing sarcoma with extra-pulmonary dissemination.
View Article and Find Full Text PDFTargeting RNA Polymerase I in Ewing Sarcoma Treatment.
Cancer Sci
March 2025
Department of Biology, Jacksonville State University, Jacksonville, Alabama, USA.
Pharmacologic inhibition of RNA polymerase I activity represents a new therapeutic approach for Ewing sarcoma. This is the first time key components of the ribosome biogenesis pathway have been linked to Ewing sarcoma biology.
View Article and Find Full Text PDFExtra Skeletal Ewing's Sarcoma of Sino Nasal Tract-A Rare Entity a Case Report.
Indian J Otolaryngol Head Neck Surg
January 2025
Department of Radiodiagnosis, IGMC, Shimla, 171001 Himachal Pradesh India.
Ewing's sarcoma is a rare and highly malignant tumour predominantly affecting the bones. Extra skeletal Ewing's sarcoma of Sino nasal tract, encompassing the nasal cavity and paranasal sinuses is an exceedingly rare location for this tumour. We present a case of a 16 year-old boy who presented with right nasal obstruction, epistaxis and right facial swelling since 3 months.
View Article and Find Full Text PDFEWS-RNA Binding Protein 1: Structural Insights into Ewing Sarcoma by Conformational Dynamics Investigations.
Curr Cancer Drug Targets
March 2025
The Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, Columbus, OH 43205, USA.
Background: Prior research has demonstrated that proteins play a significant role in the prognosis and treatments of various sarcomas, including Ewing sarcoma through the interplay of downstream signaling cascades. However, there is limited understanding about the strcucture conformation of EWSR1 and its structural implication in the prognosis of Ews-ing Sarcoma by interaction with RNA molecules.
Aims: The primary goal of ongoing research is to determine how EWSR1 contributes to Ewing sarcoma.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!